AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02669186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
Study NCT04552873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered.
Study NCT04552873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
Study NCT04457648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manuka honey 16% eye drops ( Optimel )
Description: 16% manuka honey eye drops, australian FDA approved
Study NCT04457648 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: systane eye drops
Description: systane lubricant eye drops
Study NCT00871559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN421(SAR153192)
Study NCT03062891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online CBT for insomnia
Description: See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
Study NCT04614259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis
Study NCT04614259 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: i.v. analgesia
Description: Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes
Study NCT00582582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus doxercalciferol
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
Study NCT00582582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel plus placebo
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
Study NCT03529630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inverted syringe
Description: Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
Study NCT02279641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study NCT02279641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Study NCT04411290 — intervention group
Intervention type: PROCEDURE
Intervention: Total thyroidectomy (TT)
Description: Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
Study NCT04060940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy: 8-session version
Description: Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
Study NCT04060940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy: 16-session version
Description: Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
Study NCT00725426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Study NCT02207829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium 62.5 mcg once daily in the morning via nDPI
Study NCT02207829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium matching placebo
Description: Umeclidinium matching placebo once daily in the morning via nDPI
Study NCT02207829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
Study NCT02207829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium matching placebo
Description: Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
Study NCT02952235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SPF100+
Description: Sun protection
Study NCT00215943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
Study NCT01461590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood
Description: 30mls/kg transfused over fours hours
Study NCT01461590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: 30mls/kg transfused over fours hours
Study NCT01461590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood
Description: 20mls/kg transfused over four hours
Study NCT01461590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: 20mls/kg transfused over four hours
Study NCT01094275 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel 75mg, Omeprazole 20mg
Description: Clopidogrel and or Omeprazole as applicable
Study NCT04589585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiVeRt
Description: DiVeRt - Vascular Reconstruction Device and Delivery System
Study NCT00965848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Study NCT00215943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
Study NCT00215943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thalidomide
Description: As outlined in Thalidomide and Dexamethasone Treatment arm
Study NCT00215943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: As outlined in VAD Treatment Arm
Study NCT00215943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: As outlined in VAD Treatment arm
Study NCT03332589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: E6201 formulated in cyclodextrin for IV administration.
Study NCT03332589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 plus dabrafenib
Description: E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
Study NCT03624023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWB-103
Description: TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
Study NCT03990376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radioisotope I-131-labeled albumin
Description: 1 mL of radioisotope I-131-labeled albumin x 2
Study NCT01563445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
Study NCT01563445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
Study NCT03190941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study NCT03190941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT03190941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-KRAS G12V mTCR PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
Study NCT03190941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
Study NCT02014298 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: non-ablative fractional laser
Description: 3 treatments with 4-6 weeks interval
Study NCT02014298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: observation, comparison to laser-treated area
Study NCT02333747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Hans electronic acupuncture apparatus
Description: TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
Study NCT02333747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: the Hans electronic acupuncture apparatus
Description: TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Bicalutamide
Description: Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Abiraterone
Description: Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Prednisolone
Description: Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT04034095 — intervention group
Intervention type: DRUG
Intervention: Apalutamide
Description: Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study NCT02599077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: patients assigned to this treatment receive 2 milligrams per day
Study NCT02599077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
Study NCT05582447 — intervention group
Intervention type: OTHER
Intervention: ektacytometry of red blood cells
Description: Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
Study NCT03827460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Description: Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
Study NCT03827460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual drinking
Description: Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
Study NCT03827460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Alcohol
Description: During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
Study NCT03706209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: hard gelatin capsules containing 50mg MP1032 as active ingredient
Study NCT03706209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard gelatin capsules containing no active ingredient
Study NCT03706209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules containing no active ingredient
Study NCT03596086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk (gene therapy)
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study NCT03646344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme Arginate 25 MG/ML
Description: IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Study NCT03646344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Study NCT03658720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Ibuprofen acid orodispersible tablet
Description: orodispersible tablet
Study NCT00435123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement ProStat 64 twice a day
Study NCT00435123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
Study NCT04018872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: L-arginine 6g orally daily
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Cholecalciferol 50000 IU once monthly orally
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo L-arginine
Description: placebo L-arginine once daily
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo L-arginine
Description: placebo L-arginine once daily
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Vitamin D
Description: placebo vitamin D orally once monthly
Study NCT00677339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin D
Description: placebo vitamin D orally once monthly
Study NCT04127032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSP Wellbeing Course
Description: A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
Study NCT03144726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
Study NCT03144726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard dressing
Description: A standard dressing will be applied to the amputations in this arm of the study
Study NCT04275648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AsthmaTuner exercise field test
Description: AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
Study NCT02835014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental Health Symptoms
Description: Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
Study NCT02835014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-efficacy regarding self-care and diabetes management
Description: Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
Study NCT02835014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Parenting Styles
Description: Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
Study NCT04261816 — intervention group
Intervention type: PROCEDURE
Intervention: extubation in the operating room
Description: Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
Study NCT04261816 — intervention group
Intervention type: PROCEDURE
Intervention: extubation in the ICU
Description: Patients who underwent liver transplantation extubation in the ICU following liver transplantation
Study NCT02787616 — intervention group
Intervention type: GENETIC
Intervention: buccal swab
Description: cheek swab for DNA sampling